Cargando…

Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination

OBJECTIVE: The purpose of this study was to assess the potential immunosuppressive role of daclizumab, a humanized monoclonal antibody against the α chain of the interleukin 2 receptor, in vivo, by comparing immune responses to the 2013 seasonal influenza vaccination between patients with multiple s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Yen Chih, Winokur, Paige, Blake, Andrew, Wu, Tianxia, Manischewitz, Jody, King, Lisa R., Romm, Elena, Golding, Hana, Bielekova, Bibiana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733151/ https://www.ncbi.nlm.nih.gov/pubmed/26848487 http://dx.doi.org/10.1212/NXI.0000000000000196

Ejemplares similares

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
por: Lin, Yen Chih, et al.
Publicado: (2015)

Pharmacodynamic effects of daclizumab in the intrathecal compartment
por: Komori, Mika, et al.
Publicado: (2017)

Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects
por: Stein, Jason, et al.
Publicado: (2018)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
por: Elkins, J., et al.
Publicado: (2015)

A Rapid Flp-In System for Expression of Secreted H5N1 Influenza Hemagglutinin Vaccine Immunogen in Mammalian Cells
por: Lu, Hanxin, et al.
Publicado: (2011)

A vital role for IL-2 trans-presentation in DC-mediated T cell activation in humans as revealed by daclizumab therapy
por: Wuest, Simone C., et al.
Publicado: (2011)

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
por: Scheibe, Franziska, et al.
Publicado: (2018)

GFAPα IgG-associated encephalitis upon daclizumab treatment of MS
por: Luessi, Felix, et al.
Publicado: (2018)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Management of MS Patients Treated With Daclizumab – a Case Series of 267 Patients
por: Rommer, Paulus S., et al.
Publicado: (2020)

Properly Folded Bacterially Expressed H1N1 Hemagglutinin Globular Head and Ectodomain Vaccines Protect Ferrets against H1N1 Pandemic Influenza Virus
por: Khurana, Surender, et al.
Publicado: (2010)

Antigenic Fingerprinting of H5N1 Avian Influenza Using Convalescent Sera and Monoclonal Antibodies Reveals Potential Vaccine and Diagnostic Targets
por: Khurana, Surender, et al.
Publicado: (2009)

Idebenone does not inhibit disability progression in primary progressive MS
por: Kosa, Peter, et al.
Publicado: (2020)

A Complex Role of Herpes Viruses in the Disease Process of Multiple Sclerosis
por: Wuest, Simone C., et al.
Publicado: (2014)

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
por: Komori, Mika, et al.
Publicado: (2016)

Oral Priming with Replicating Adenovirus Serotype 4 Followed by Subunit H5N1 Vaccine Boost Promotes Antibody Affinity Maturation and Expands H5N1 Cross-Clade Neutralization
por: Khurana, Surender, et al.
Publicado: (2015)

Cerebrospinal Fluid IL-12p40, CXCL13 and IL-8 as a Combinatorial Biomarker of Active Intrathecal Inflammation
por: Bielekova, Bibiana, et al.
Publicado: (2012)

Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity
por: Masvekar, Ruturaj, et al.
Publicado: (2021)

AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization
por: Khurana, Surender, et al.
Publicado: (2018)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016)

Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS)
por: Jia, Yan, et al.
Publicado: (2012)

Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
por: Reardon, Jennifer, et al.
Publicado: (2013)

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program
por: Gold, Ralf, et al.
Publicado: (2016)

Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry
por: Ranganath, Thanmayi, et al.
Publicado: (2020)

Pioglitazone regulates myelin phagocytosis and multiple sclerosis monocytes
por: Natrajan, Muktha S., et al.
Publicado: (2015)

DRESS Syndrome and Daclizumab Failure—Were Potentially Dangerous Signs Missed in Clinical Trials?
por: Avasarala, Jagannadha
Publicado: (2018)

Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
por: Karunaratne, Kushan, et al.
Publicado: (2021)

Effects of Exenatide Alone and in Combination With Daclizumab on β-Cell Function in Long-Standing Type 1 Diabetes
por: Rother, Kristina I., et al.
Publicado: (2009)

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation
por: Sageshima, Junichiro, et al.
Publicado: (2009)

A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation
por: Mullen, John C, et al.
Publicado: (2014)

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
Publicado: (2021)

Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease
por: Rager, Alison, et al.
Publicado: (2010)

Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment
por: Kosa, Peter, et al.
Publicado: (2016)

A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin
por: Yu, Fei, et al.
Publicado: (2017)

Efficacy of Anti-Interleukin-2 Receptor Antibody (Daclizumab) in Reducing the Incidence of Acute Rejection After Renal Transplantation
por: Saghafi, Hossein, et al.
Publicado: (2012)

Current Status and Future Opportunities in Modeling Clinical Characteristics of Multiple Sclerosis
por: Liu, Joshua, et al.
Publicado: (2022)

Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
por: Tran, Jonathan Q, et al.
Publicado: (2016)

Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
por: Benedict, Ralph HB, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2d1d0jkev28q3lhemk4ti91na0